These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12741437)

  • 41. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination drug therapy for dyslipidemia.
    Alaswad K; O'Keefe JH; Moe RM
    Curr Atheroscler Rep; 1999 Jul; 1(1):44-9. PubMed ID: 11122691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical update on the use of niacin for the treatment of dyslipidemia.
    Berra K
    J Am Acad Nurse Pract; 2004 Dec; 16(12):526-34. PubMed ID: 15645997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins.
    Gaw A
    Cardiovasc Drugs Ther; 2003 Jan; 17(1):53-62. PubMed ID: 12843687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of drugs on high-density lipoprotein.
    McKenney JM
    J Clin Lipidol; 2007 Mar; 1(1):74-87. PubMed ID: 21291670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
    McKenney JM; Jones PH; Bays HE; Knopp RH; Kashyap ML; Ruoff GE; McGovern ME
    Atherosclerosis; 2007 Jun; 192(2):432-7. PubMed ID: 17239888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.
    Agouridis AP; Filippatos TD; Tsimihodimos V; Elisaf MS
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):355-66. PubMed ID: 21438815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fibrates and niacin: is there a place for them in clinical practice?
    Wierzbicki AS; Viljoen A
    Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
    Sprecher DL
    Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.